We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NiSource (NI) to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
NiSource Inc. (NI - Free Report) is scheduled to release second-quarter 2018 earnings results on Aug 1, before the opening bell. In the last reported quarter, the company’s earnings were in line with the consensus mark.
Let’s see how things are shaping up for this utility prior to the earnings announcement.
Factors to Consider
NiSource has a 100% regulated utility business model. The new gas rates approved at the beginning of 2018 and during the quarter are likely to have a positive impact on earnings. We expect that the company will gain from the modernization program which ensures continued timely recovery of 75% infrastructure investments in less than 12 months.
For the to-be-reported quarter, the Zacks Consensus Estimate for NiSource’s revenues is pegged at $999.3 million, reflecting a year-over-year increase of 0.88%.
Earnings Whispers
According to our proven model, a stock needs to have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to beat estimates. However, NiSource does not have the correct combination for an earnings beat as elaborated below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: The company’s Earnings ESP is -8.11%.
Zacks Rank: NiSource carries a Zacks Rank #3. The company’s favorable Zacks Rank when combined with the negative ESP makes an earnings beat unlikely this season.
Conversely, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is witnessing negative estimate revisions.
Stocks to Consider
NiSource does not have the right combination but there are few other companies in the industry that are likely to beat estimates this earnings season.
Alliant Energy Corp. (LNT - Free Report) is expected to release second-quarter results on Aug 2, 2018. It has an Earnings ESP of +1.10% and a Zacks Rank #2.
Dominion Energy Inc. (D - Free Report) is expected to release second-quarter results on Aug 1, 2018. It has an Earnings ESP of +0.84% and a Zacks Rank #2.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
NiSource (NI) to Report Q2 Earnings: What's in the Cards?
NiSource Inc. (NI - Free Report) is scheduled to release second-quarter 2018 earnings results on Aug 1, before the opening bell. In the last reported quarter, the company’s earnings were in line with the consensus mark.
Let’s see how things are shaping up for this utility prior to the earnings announcement.
Factors to Consider
NiSource has a 100% regulated utility business model. The new gas rates approved at the beginning of 2018 and during the quarter are likely to have a positive impact on earnings. We expect that the company will gain from the modernization program which ensures continued timely recovery of 75% infrastructure investments in less than 12 months.
For the to-be-reported quarter, the Zacks Consensus Estimate for NiSource’s revenues is pegged at $999.3 million, reflecting a year-over-year increase of 0.88%.
Earnings Whispers
According to our proven model, a stock needs to have the right combination of two key ingredients — a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) — to beat estimates. However, NiSource does not have the correct combination for an earnings beat as elaborated below.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: The company’s Earnings ESP is -8.11%.
NiSource, Inc Price and EPS Surprise
NiSource, Inc Price and EPS Surprise | NiSource, Inc Quote
Zacks Rank: NiSource carries a Zacks Rank #3. The company’s favorable Zacks Rank when combined with the negative ESP makes an earnings beat unlikely this season.
Conversely, we caution against stocks with a Zacks Rank #4 or 5 (Sell-rated) going into the earnings announcement, especially when the company is witnessing negative estimate revisions.
Stocks to Consider
NiSource does not have the right combination but there are few other companies in the industry that are likely to beat estimates this earnings season.
Alliant Energy Corp. (LNT - Free Report) is expected to release second-quarter results on Aug 2, 2018. It has an Earnings ESP of +1.10% and a Zacks Rank #2.
Algonquin Power & Utilities Corp. (AQN - Free Report) is anticipated to release second-quarter results on Aug 9, 2018. It has an Earnings ESP of +15.38% and carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Dominion Energy Inc. (D - Free Report) is expected to release second-quarter results on Aug 1, 2018. It has an Earnings ESP of +0.84% and a Zacks Rank #2.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>